Status:
COMPLETED
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Lead Sponsor:
Bausch & Lomb Incorporated
Collaborating Sponsors:
NicOx Inc.
Conditions:
Primary Open Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of PF 03187207.
Eligibility Criteria
Inclusion
- Diagnosis of primary open angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in one or both eyes
Exclusion
- Closed or barely open anterior chamber angle or a history of acute angle closure in either eye
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT00441883
Start Date
March 1 2007
End Date
July 1 2008
Last Update
September 14 2020
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Artesia, California, United States, 90701
2
Pfizer Investigational Site
Newport Beach, California, United States, 92663
3
Pfizer Investigational Site
Petaluma, California, United States, 94954
4
Pfizer Investigational Site
Poway, California, United States, 92064